Method of Treating Graft Versus Host Disease
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/AU2011/000840, filed Jul 4, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,105,394 | Method of Treating Graft Versus Host Disease In force · Medium confidence | Mesoblast, Inc. | In force | Medium confidence | ||
| US 10,849,932 | Method of Treating Graft Versus Host Disease In force · Medium confidence | Mesoblast, Inc. | In force | Medium confidence | ||
| US 9,301,978 | Method of Treating Graft Versus Host Disease In force · High confidence | Mesoblast, Inc. | In force | High confidence | ||
| Application 17/077,698 | Method of Treating Graft Versus Host Disease Abandoned Abandoned Jul 27, 2023 | Mesoblast, Inc. | Abandoned | Abandoned Jul 27, 2023 | ||
| Application 18/192,398 | Method of Treating Graft Versus Hot Disease Pending Not granted | Mesoblast, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Mesoblast, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.